In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best American dividend stocks. Dividend-paying stocks have long benefited investors by ...

Johnson & Johnson (JNJ) beat Wall Street expectations in its first-quarter earnings report and raised its 2025 sales forecast by $700 million, even though sales are expected to dip due to the loss ...

In a report released today, Matt Miksic from Barclays maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a price target of $166.00. Discover outperforming stocks and ...

Johnson & Johnson (NYSE: JNJ) recently released its Q1 earnings, surpassing analyst estimates on both revenue and earnings. The company posted adjusted earnings of $2.77 per share on revenue of $ ...

Johnson & Johnson JNJ and Pfizer PFE are two of the world’s largest pharmaceutical companies with diversified healthcare portfolios. J&J operates through pharmaceuticals and medical devices ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other value stocks in Ken Fisher’s portfolio. Trump’s “stupid” tariffs will fail ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Matt Winkelmeyer/Getty Mark Hoppus's new book has several revelations — including how he discovered he was battling OCD. In new memoir Fahrenheit-182, the Blink-182 rocker, now 53, reveals how ...